Bruce N. Jacobs - 01 Mar 2023 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role: Chief Financial Officer
Signature: /s/ Bruce N. Jacobs
Issuer symbol: KYMR
Transactions as of: 01 Mar 2023
Net transactions value: -$42,465
Form type: 4
Filing time: 03 Mar 2023, 15:30:13 UTC
Previous filing: 24 Oct 2022
Next filing: 02 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KYMR	Common Stock	Award	$0	+23,750	+29%	$0.000000	105,938	01 Mar 2023	Direct	F1, F2
transaction	KYMR	Common Stock	Sale	$32,607	-1,056	-1%	$30.88	104,882	02 Mar 2023	Direct	F3, F4
transaction	KYMR	Common Stock	Sale	$9,859	-314	-0.3%	$31.40	104,568	02 Mar 2023	Direct	F3, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KYMR	Stock Option (Right to Buy)	Award	$0	+142,500		$0.000000	142,500	01 Mar 2023	Common Stock	142,500	$32.07	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date.
F2	This number includes 909 shares acquired under the Registrant's employee stock purchase plan on December 1, 2022.
F3	Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.30 to $31.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.32 to $31.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6	The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date.